Survival benefit of chemoradiotherapy in limited-stage mantle cell lymphoma: a National Cancer Database analysis.
Combined chemotherapy and radiation may improve outcomes for the rare patients with limited-stage mantle cell lymphoma.
Limited-stage mantle cell lymphoma (MCL) is rare, and optimal management remains undefined because of limited representation in clinical studies. These findings suggest that combined-modality therapy may be preferred for appropriately selected patients with limited-stage MCL.
What the study was
- Study design
- Cohort study
- Population
- cancer patients
- Sample size
- 2428
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Blood neoplasia
Why it surfaced
Score 6/10 [PROMISING_PRELIMINARY]: Cohort study (Journal Article) matched 'Hematologic malignancies'. Components — novelty:1/3, relevance:2/3, design:1/2, population:2/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.